• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Seminar spotlights ophthalmic research

Article

"A seminar designed to help investors identify opportunities and evaluate potential investment in ophthalmic research will take place in Fort Lauderdale, FL, April 29. The seminar, entitled ?Unmet Needs: Emerging Frontiers in Ophthalmic Science,? is being organized by the Association for Research in Vision and Ophthalmology (ARVO) Foundation for Eye Research (AFER). "

Rockville, MD -A seminar designed to help investors identify opportunities and evaluate potential investment in ophthalmic research will take place in Fort Lauderdale, FL, April 29.

The seminar, entitled “Unmet Needs: Emerging Frontiers in Ophthalmic Science,” is being organized by the Association for Research in Vision and Ophthalmology (ARVO) Foundation for Eye Research (AFER).

The seminar aims to help investors better understand the scientific and commercial environment of ophthalmic research. Sessions will describe unmet needs as well as promising treatments for retinal disease and ocular surface disorders.

“Modern science and industry have made tremendous progress in preventing and treating eye disease,” said lead organizer Nicolas Bazan, MD, PhD, “but there is still a great need to develop more effective treatments and devices to help alleviate these conditions. Many areas of ophthalmic science require additional research support-and they offer opportunities for commercial development.

“AFER’s Investors Seminar will provide a unique opportunity for private equity managers, venture capitalists, analysts, and others to assess the value of emerging early-  and late-stage treatments through an independent scientific and commercial lens,” Dr. Bazan continued. “They will also join in discussion with the scientists and commercial experts who are working at the cutting edge of these fields.”

The speakers will discuss the epidemiology of retinal diseases and ocular surface disorders, unmet needs, desired clinical outcomes, regulatory considerations, emergence of potential treatment algorithms, limitations of current therapies, and the drivers of market potential.

Complete program, venue and registration information is available at www.arvofoundation.org/investors.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.